Abstract
The diagnosis of ductal carcinoma in situ (DCIS) has increased dramatically following the widespread adoption of screening mammography. DCIS has a favorable prognosis overall, but is associated with an increased risk of invasive breast cancer (IBC) and occasionally, with poor outcomes. The goal of the multidisciplinary treatment of DCIS is to prevent the development of invasive disease. The identification of patients at elevated risk for progression or recurrence who require more aggressive multimodality therapy and, conversely, those who can safely forgo elements of the current therapeutic armamentarium are important current challenges.
Keywords: Ductal Carcinoma in Situ, DCIS, Controversies, Clinical Trials
Current Cancer Therapy Reviews
Title:Ductal Carcinoma In Situ: Clinical Trials Update and Resolving Controversies
Volume: 8 Issue: 3
Author(s): Robert E. Roses and Henry M. Kuerer
Affiliation:
Keywords: Ductal Carcinoma in Situ, DCIS, Controversies, Clinical Trials
Abstract: The diagnosis of ductal carcinoma in situ (DCIS) has increased dramatically following the widespread adoption of screening mammography. DCIS has a favorable prognosis overall, but is associated with an increased risk of invasive breast cancer (IBC) and occasionally, with poor outcomes. The goal of the multidisciplinary treatment of DCIS is to prevent the development of invasive disease. The identification of patients at elevated risk for progression or recurrence who require more aggressive multimodality therapy and, conversely, those who can safely forgo elements of the current therapeutic armamentarium are important current challenges.
Export Options
About this article
Cite this article as:
E. Roses Robert and M. Kuerer Henry, Ductal Carcinoma In Situ: Clinical Trials Update and Resolving Controversies, Current Cancer Therapy Reviews 2012; 8 (3) . https://dx.doi.org/10.2174/157339412802653173
DOI https://dx.doi.org/10.2174/157339412802653173 |
Print ISSN 1573-3947 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6301 |
Call for Papers in Thematic Issues
Advancements in Lipid Nanoparticle Delivery Systems for mRNA Therapeutics
The thematic issue will focus on key areas such as lipid nanoparticles, mRNA therapeutics, drug delivery systems, nanotechnology in medicine, targeted therapy, non-viral vectors, precision medicine, and biomedical engineering.read more
Current progress in Protein Degradation and Cancer Therapy
argeted Protein Degradation is gaining momentum in cancer therapy, it facilitate targeting undruggable proteins, it overcome cancer resistance and avoid undesirable side effects. Thus small molecules degraders have emerged as novel therapeutic strategy. Targeted protein degradation (TPD), the process of eliminating a protein of interest hold a great promise for ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Non Steroidal Anti Inflammatory Drugs As Gatekeepers Of Colon Carcinoma Highlight New Scenarios Beyond Cyclooxygenases Inhibition
Current Cancer Drug Targets On the Role of Rab5 in Cell Migration
Current Molecular Medicine Targeting Nodal and Cripto-1: Perspectives Inside Dual Potential Theranostic Cancer Biomarkers
Current Medicinal Chemistry Radiopharmaceuticals for Oncology Drug Development: A Pharmaceutical Industry Perspective
Current Pharmaceutical Design Vascular Endothelial Growth Factor as an Anti-Angiogenic Target for Cancer Therapy
Current Drug Targets Dendrimers as Novel Systems for Delivery of Neuropharmaceuticals to the Brain
CNS & Neurological Disorders - Drug Targets Peroxisome Proliferator-Activated Receptors: The Nutritionally Controlled Molecular Networks that Integrate Inflammation, Immunity and Metabolism
Current Nutrition & Food Science Drug Repurposing: An Emerging Tool for Drug Reuse, Recycling and Discovery
Current Drug Research Reviews Identification of Novel Breast Cancer Genes based on Gene Expression Profiles and PPI Data
Current Proteomics Metformin Restrains Pancreatic Duodenal Homeobox-1 (PDX-1) Function by Inhibiting ERK Signaling in Pancreatic Ductal Adenocarcinoma.
Current Molecular Medicine Antitubulinic effect of New Fluorazone Derivatives on Melanoma Cells
Anti-Cancer Agents in Medicinal Chemistry A Review on Designing Poly (Lactic-co-glycolic Acid) Nanoparticles as Drug Delivery Systems
Pharmaceutical Nanotechnology RNA Interference (RNAi) Patents and Human Health Related Applications of RNAi
Recent Patents on DNA & Gene Sequences TRAIL: A Sword for Killing Tumors
Current Medicinal Chemistry Novel Targets for Apoptosis Modulation: BAG3 Protein and Other Co- Chaperones
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery Direct Inhibitors of Ras-Effector Protein Interactions
Mini-Reviews in Medicinal Chemistry The Mechanism of Calcitriol in Cancer Prevention and Treatment
Current Medicinal Chemistry Isolation of Bioactive Natural Products from Myxomycetes
Medicinal Chemistry Development of Prolactin Receptor Antagonists: Same Goal, Different Ways
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery Meet Our Editorial Board Member
Letters in Drug Design & Discovery